Potential of carbohydrate-binding agents as therapeutics against enveloped viruses

Medicinal Research Reviews

Volumn 32, Issue 2, 2012, Pages 349-387

  Francois K O ^a   Balzarini, J ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Carbohydrate binding agent (CBA); HIV 1; Innate immune system; Lectin; N linked glycan

Indexed keywords

ACTINOHIVIN; BENANOMICIN A; CARBOHYDRATE BINDING PROTEIN; CYANOVIRIN N; DEFENSIN; GRIFFITHSIN; LANGERIN; LECTIN; LUNG SURFACTANT; MANNOSE BINDING LECTIN; MERMAID; MICROBICIDE; NEUTRALIZING ANTIBODY; OSELTAMIVIR; PRADIMICIN A; PRADIMICIN C; PRADIMICIN S; SCYTOVIRIN; SIALIC ACID; UNCLASSIFIED DRUG; ZANAMIVIR;

ACTINOBACTERIA; ALGA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CORAL; CYANOBACTERIUM; DENDRITIC CELL; DIARRHEA; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; INFLUENZA; INNATE IMMUNITY; INVERTEBRATE; LACTOBACILLUS; MEDICINAL PLANT; NAUSEA AND VOMITING; NONHUMAN; PROTEIN INTERACTION; VERTEBRATE; VIRUS ENVELOPE;

ANTIVIRAL AGENTS; BACTERIAL PROTEINS; CARRIER PROTEINS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; LECTINS; RECEPTORS, CELL SURFACE; VIRAL ENVELOPE PROTEINS;

EID: 84857668552     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20216     Document Type: Article

References (236)

1. Sharon N, Lis H. Lectins. Dordrecht: Kluwer Academic Publishers; 2003.
2. Balzarini J. Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res 2006;71:237-247.
3. Botos I, Wlodawer A. Proteins that bind high-mannose sugars of the HIV envelope. Prog Biophys Mol Biol 2005;88:233-282.
4. Bertaux C, Daelemans D, Meertens L, Cormier EG, Reinus JF, Peumans WJ, Van Damme EJ, Igarashi Y, Oki T, Schols D, Dragic T, Balzarini J. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology 2007;366:40-50.
5. Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem 2006;281:25177-25183.
6. Alen MM, Kaptein SJ, De Burghgraeve T, Balzarini J, Neyts J, Schols D. Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. Virology 2009;387:67-75.
7. Keyaerts E, Vijgen L, Pannecouque C, Van Damme E, Peumans W, Egberink H, Balzarini J, Van Ranst M. Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res 2007;75:179-187.
8. van der Meer FJ, de Haan CAM, Schuurman NMP, Haijema BJ, Peumans WJ, Van Damme EJM, Delputte PL, Balzarini J, Egberink HF. Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture. Antiviral Res 2007;76:21-29.
9. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990;265:10373-10382.
10. Pohlmann S, Zhang J, Baribaud F, Chen Z, Leslie GJ, Lin G, Granelli-Piperno A, Doms RW, Rice CM, McKeating JA. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol 2003;77:4070-4080.
11. Ferri C, La Civita L, Zignego AL. Extrahepatic manifestations of hepatitis C virus infection. Ann Intern Med 1996;125:344; author reply 346.
12. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457:882-886.
13. Op De Beeck A, Cocquerel L, Dubuisson J. Biogenesis of hepatitis C virus envelope glycoproteins. J Gen Virol 2001;82:2589-2995.
14. Meunier JC, Fournillier A, Choukhi A, Cahour A, Cocquerel L, Dubuisson J, Wychowski C. Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. J Gen Virol 1999;80:887-896.
15. Iacob RE, Perdivara I, Przybylski M, Tomer KB. Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans. J Am Soc Mass Spectrom 2008;19:428-444.
16. Abada P, Noble B, Cannon PM. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol 2005;79:3627-3638.
17. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S, McKeating JA. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 1999;73:6235-6244.
18. Flint M, Thomas JM, Maidens CM, Shotton C, Levy S, Barclay WS, McKeating JA. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol 1999;73:6782-6790.
19. Li HF, Huang CH, Ai LS, Chuang CK, Chen SS. Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: Involvement in cell fusion and virus entry. J Biomed Sci 2009;16:89.
20. Halstead SB. Dengue. Lancet 2007;370:1644-1652.
21. Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005;3:13-22.
22. Perera R, Khaliq M, Kuhn RJ. Closing the door on flaviviruses: Entry as a target for antiviral drug design. Antiviral Res 2008;80:11-22.
23. Rey FA. Dengue virus envelope glycoprotein structure: New insight into its interactions during viral entry. Proc Natl Acad Sci USA 2003;100:6899-6901.
24. Hacker K, White L, de Silva AM. N-linked glycans on dengue viruses grown in mammalian and insect cells. J Gen Virol 2009;90:2097-2106.
25. Chow LP, Chiu LL, Khoo KH, Peng HJ, Yang SY, Huang SW, Su SN. Purification and structural analysis of the novel glycoprotein allergen Cyn d 24, a pathogenesis-related protein PR-1, from Bermuda grass pollen. Febs J 2005;272:6218-6227.
26. Hsiao ESL, Chen JCF, Tsai HY, Khoo KH, Chen ST, Tzen JTC. Determination of N-glycosylation site and glycan structures of pectin methylesterase in jelly fig (Ficus awkeotsang) Achenes. J Agr Food Chem 2009;57:6757-6763.
27. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7:226-236.
28. Voss D, Pfefferle S, Drosten C, Stevermann L, Traggiai E, Lanzavecchia A, Becker S. Studies on membrane topology, N-glycosylation and functionality of SARS-CoV membrane protein. Virol J 2009;6:79.
29. Krokhin O, Li Y, Andonov A, Feldmann H, Flick R, Jones S, Stroeher U, Bastien N, Dasuri KV, Cheng K, Simonsen JN, Perreault H, Wilkins J, Ens W, Plummer F, Standing KG. Mass spectrometric characterization of proteins from the SARS virus: A preliminary report. Mol Cell Proteomics 2003;2:346-356.
30. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem 2000;69:531-569.
31. Ohuchi R, Ohuchi M, Garten W, Klenk HD. Oligosaccharides in the stem region maintain the influenza virus hemagglutinin in the metastable form required for fusion activity. J Virol 1997;71:3719-3725.
32. Keil W, Geyer R, Dabrowski J, Dabrowski U, Niemann H, Stirm S, Klenk HD. Carbohydrates of influenza virus. Structural elucidation of the individual glycans of the FPV hemagglutinin by two-dimensional 1H n.m.r. and methylation analysis. EMBO J 1985;4:2711-2720.
33. Arp J, LeVatte M, Rowe J, Perkins S, King E, Leystra-Lantz C, Foung SK, Dekaban GA. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: Expression of gp46 by the vaccinia virus/T7 polymerase system. J Virol 1996;70:7349-7359.
34. Delamarre L, Rosenberg AR, Pique C, Pham D, Callebaut I, Dokhelar MC. The HTLV-I envelope glycoproteins: Structure and functions. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13:S85-S91.
35. Akhtar J, Shukla D. Viral entry mechanisms: Cellular and viral mediators of herpes simplex virus entry. Febs J 2009;276:7228-7236.
36. Reske A, Pollara G, Krummenacher C, Chain BM, Katz DR. Understanding HSV-1 entry glycoproteins. Rev Med Virol 2007;17:205-215.
37. Spear PG. Herpes simplex virus: Receptors and ligands for cell entry. Cell Microbiol 2004;6:401-410.
38. Rasmussen L, Nelson M, Neff M, Merigan TC, Jr. Characterization of two different human cytomegalovirus glycoproteins which are targets for virus neutralizing antibody. Virology 1988;163:308-318.
39. Balzarini J, Neyts J, Schols D, Hosoya M, Van Damme E, Peumans W, De Clercq E. The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. Antiviral Res 1992;18:191-207.
40. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina JH, 2nd, Buckheit RW, Jr, Nara PL, Pannell LK, Sowder RC, 2nd, Henderson LE. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development. Antimicrob Agents Chemother 1997;41:1521-1530.
41. Bewley CA. Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: Structural basis for high-affinity carbohydrate-mediated binding to gp120. Structure 2001;9:931-940.
42. Yang F, Bewley CA, Louis JM, Gustafson KR, Boyd MR, Gronenborn AM, Clore GM, Wlodawer A. Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. J Mol Biol 1999;288:403-412.
43. Smee DF, Bailey KW, Wong MH, O'Keefe BR, Gustafson KR, Mishin VP, Gubareva LV. Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N. Antiviral Res 2008;80:266-271.
44. Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR. Cyanovirin-N binds to the viral surface glycoprotein, GP1, 2 and inhibits infectivity of Ebola virus. Antiviral Res 2003;58:47-56.
45. Barrientos LG, Gronenborn AM. The highly specific carbohydrate-binding protein cyanovirin-N: Structure, anti-HIV/Ebola activity and possibilities for therapy. Mini Rev Med Chem 2005;5:21-31.
46. Tiwari V, Shukla SY, Shukla D. A sugar binding protein cyanovirin-N blocks herpes simplex virus type-1 entry and cell fusion. Antiviral Res 2009;84:67-75.
47. Tsai CC, Emau P, Jiang YH, Agy MB, Shattock RJ, Schmidt A, Morton WR, Gustafson KR, Boyd MR. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004;20:11-18.
48. Tsai CC, Emau P, Jiang Y, Tian B, Morton WR, Gustafson KR, Boyd MR. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2003;19:535-541.
49. Liu X, Lagenaur LA, Simpson DA, Essenmacher KP, Frazier-Parker CL, Liu Y, Tsai D, Rao SS, Hamer DH, Parks TP, Lee PP, Xu Q. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother 2006;50:3250-3259.
50. Pusch O, Boden D, Hannify S, Lee F, Tucker LD, Boyd MR, Wells JM, Ramratnam B. Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin. J Acquir Immune Defic Syndr 2005;40:512-520.
51. Huskens D, Vermeire K, Vanderneulebroucke E, Balzarini J, Schols D. Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. Int J Biochem Cell Biol 2008;40:2802-2814.
52. Yamaguchi M, Ogawa T, Muramoto K, Kamio Y, Jimbo M, Kamiya H. Isolation and characterization of a mannan-binding lectin from the freshwater cyanobacterium (blue-green algae) Microcystis viridis. Biochem Biophys Res Commun 1999;265:703-708.
53. Williams DC, Jr, Lee JY, Cai M, Bewley CA, Clore GM. Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man3GlcNAc2: Structural basis for specificity and high-affinity binding to the core pentasaccharide from n-linked oligomannoside. J Biol Chem 2005;280:29269-29276.
54. Bokesch HR, O'Keefe BR, McKee TC, Pannell LK, Patterson GM, Gardella RS, Sowder RC, 2nd, Turpin J, Watson K, Buckheit RW, Jr, Boyd MR. A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry 2003;42:2578-2584.
55. Xiong C, O'Keefe BR, Byrd RA, McMahon JB. Potent anti-HIV activity of scytovirin domain 1 peptide. Peptides 2006;27:1668-1675.
56. Sato Y, Okuyama S, Hori K. Primary structure and carbohydrate binding specificity of a potent anti-HIV lectin isolated from the filamentous cyanobacterium Oscillatoria agardhii. J Biol Chem 2007;282:11021-11029.
57. Kljajic Z, Schroder HC, Rottmann M, Cuperlovic M, Movsesian M, Uhlenbruck G, Gasic M, Zahn RK, Muller WE. A D-mannose-specific lectin from Gerardia savaglia that inhibits nucleocytoplasmic transport of mRNA. Eur J Biochem 1987;169:97-104.
58. Muller WE, Renneisen K, Kreuter MH, Schroder HC, Winkler I. The D-mannose-specific lectin from Gerardia savaglia blocks binding of human immunodeficiency virus type I to H9 cells and human lymphocytes in vitro. J Acquir Immune Defic Syndr 1988;1:453-458.
59. Chiba H, Inokoshi J, Okamoto M, Asanuma S, Matsuzaki K, Iwama M, Mizumoto K, Tanaka H, Oheda M, Fujita K, Nakashima H, Shinose M, Takahashi Y, Omura S. Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: Isolation, characterization, and biological activities. Biochem Biophys Res Commun 2001;282:595-601.
60. Chiba H, Inokoshi J, Nakashima H, Omura S, Tanaka H. Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120. Biochem Biophys Res Commun 2004;316:203-210.
61. Tanaka H, Chiba H, Inokoshi J, Kuno A, Sugai T, Takahashi A, Ito Y, Tsunoda M, Suzuki K, Takenaka A, Sekiguchi T, Umeyama H, Hirabayashi J, Omura S. Mechanism by which the lectin actinohivin blocks HIV infection of target cells. Proc Natl Acad Sci USA 2009;106:15633-15638.
62. Mori T, O'Keefe BR, Sowder RC, 2nd, Bringans S, Gardella R, Berg S, Cochran P, Turpin JA, Buckheit RW, Jr, McMahon JB, Boyd MR. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 2005;280:9345-9353.
63. Emau P, Tian B, O'Keefa BR, Mori T, McMahon JB, Palmer KE, Jiang Y, Bekele G, Tsai CC. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol 2007;36:244-253.
64. O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, Mirsalis J, d'Andrea AL, Hume SD, Bratcher B, Saucedo CJ, McMahon JB, Pogue GP, Palmer KE. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci USA 2009;106:6099-6104.
65. Ziolkowska NE, O'Keefe BR, Mori T, Zhu C, Giomarelli B, Vojdani F, Palmer KE, McMahon JB, Wlodawer A. Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 2006;14:1127-1135.
66. Balzarini J, Schols D, Neyts J, Van Damme E, Peumans W, De Clercq E. Alpha-(1-3)- and alpha-(1-6)-d-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob Agents Chemother 1991;35:410-416.
67. Van Damme EJM, Peumans WJ, Pusztai A, Bardocz S. Handbook of plant lectins: Properties and biomedical applications. Chichester: John Wiley & Sons Ltd.; 1998.
68. Balzarini J, Van Laethem K, Hatse S, Froeyen M, Peumans W, Van Damme E, Schols D. Carbohydrate-binding agents cause deletions of highly conserved glycosylation sites in HIV GP120: A new therapeutic concept to hit the achilles heel of HIV. J Biol Chem 2005;280:41005-41014.
69. Charan RD, Munro MH, O'Keefe BR, Sowder R, McKee TC, Currens MJ, Pannell LK, Boyd MR. Isolation and characterization of Myrianthus holstii lectin, a potent HIV-1 inhibitory protein from the plant Myrianthus holstii(1). J Nat Prod 2000;63:1170-1174.
70. Balzarini J. Targeting the glycans of glycoproteins: A novel paradigm for antiviral therapy. Nat Rev Microbiol 2007;5:583-597.
71. Hansen JE, Nielsen CM, Nielsen C, Heegaard P, Mathiesen LR, Nielsen JO. Correlation between carbohydrate structures on the envelope glycoprotein gp120 of HIV-1 and HIV-2 and syncytium inhibition with lectins. AIDS 1989;3:635-641.
72. Lifson J, Coutre S, Huang E, Engleman E. Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus-induced cell fusion. J Exp Med 1986;164:2101-2106.
73. Swanson MD, Winter HC, Goldstein IJ, Markovitz DM. A lectin isolated from bananas is a potent inhibitor of HIV replication. J Biol Chem 2010;285:8646-8655.
74. Wang JH, Kong J, Li W, Molchanova V, Chikalovets I, Belogortseva N, Luk'yanov P, Zheng YT. A beta-galactose-specific lectin isolated from the marine worm Chaetopterus variopedatus possesses anti-HIV-1 activity. Comp Biochem Physiol C Toxicol Pharmacol 2006;142:111-117.
75. Molchanova V, Chikalovets I, Chernikov O, Belogortseva N, Li W, Wang JH, Yang DYO, Zheng YT, Lukyanov P. A new lectin from the sea worm Serpula vermicularis: Isolation, characterization and anti-HIV activity. Comp Biochem Physiol C Toxicol Pharmacol 2007;145:184-193.
76. Nabatov AA, de Jong MAWP, de Witte L, Bulgheresi S, Geijtenbeek TBH. C-type lectin Mermaid inhibits dendritic cell mediated HIV-1 transmission to CD4+T cells. Virology 2008;378:323-328.
77. Weis WI, Taylor ME, Drickamer K. The C-type lectin superfamily in the immune system. Immunol Rev 1998;163:19-34.
78. Mercier S, St-Pierre C, Pelletier I, Ouellet M, Tremblay MJ, Sato S. Galectin-1 promotes HIV-1 infectivity in macrophages through stabilization of viral adsorption. Virology 2008;371:121-129.
79. Ouellet M, Mercier S, Pelletier I, Bounou S, Roy J, Hirabayashi J, Sato S, Tremblay MJ. Galectin-1 acts as a soluble host factor that promotes HIV-1 infectivity through stabilization of virus attachment to host cells. J Immunol 2005;174:4120-4126.
80. van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol 2008;9:593-601.
81. Pulliam L, Sun B, Rempel H. Invasive chronic inflammatory monocyte phenotype in subjects with high HIV-1 viral load. J Neuroimmunol 2004;157:93-98.
82. van der Kuyl AC, van den Burg R, Zorgdrager F, Groot F, Berkhout B, Cornelissen M. Sialoadhesin (CD169) expression in CD14+cells is upregulated early after HIV-1 infection and increases during disease progression. PLoS One 2007;2:e257.
83. Rempel H, Calosing C, Sun B, Pulliam L. Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. PLoS One 2008;3:e1967.
84. Robinson MJ, Sancho D, Slack EC, LeibundGut-Landmann S, Reis e Sousa C. Myeloid C-type lectins in innate immunity. Nat Immunol 2006;7:1258-1265.
85. Figdor CG, van Kooyk Y, Adema GJ. C-type lectin receptors on dendritic cells and Langerhans cells. Nat Rev Immunol 2002;2:77-84.
86. Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, Figdor CG. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000;100:575-585.
87. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-597.
88. Pöhlmann S, Baribaud F, Lee B, Leslie GJ, Sanchez MD, Hiebenthal-Millow K, Munch J, Kirchhoff F, Doms RW. DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus. J Virol 2001;75:4664-4672.
89. Feinberg H, Mitchell DA, Drickamer K, Weis WI. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 2001;294:2163-2166.
90. Appelmelk BJ, van Die I, van Vliet SJ, Vandenbroucke-Grauls CM, Geijtenbeek TB, van Kooyk Y. Cutting edge: Carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3-grabbing nonintegrin on dendritic cells. J Immunol 2003;170:1635-1639.
91. van Liempt E, Bank CM, Mehta P, Garci AVJJ, Kawar ZS, Geyer R, Alvarez RA, Cummings RD, Kooyk YV, van Die I. Specificity of DC-SIGN for mannose- and fucose-containing glycans. FEBS Lett 2006;580:6123-6131.
92. Lee B, Leslie G, Soilleux E, O'Doherty U, Baik S, Levroney E, Flummerfelt K, Swiggard W, Coleman N, Malim M, Doms RW. cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. J Virol 2001;75:12028-12038.
93. Rappocciolo G, Piazza P, Fuller CL, Reinhart TA, Watkins SC, Rowe DT, Jais M, Gupta P, Rinaldo CR. DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS Pathog 2006;2:e70.
94. Baribaud F, Pohlmann S, Doms RW. The role of DC-SIGN and DC-SIGNR in HIV and SIV attachment, infection, and transmission. Virology 2001;286:1-6.
95. Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 2002;16:135-144.
96. Trumpfheller C, Park CG, Finke J, Steinman RM, Granelli-Piperno A. Cell type-dependent retention and transmission of HIV-1 by DC-SIGN. Int Immunol 2003;15:289-298.
97. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M, Dable J, Stossel H, Romani N, Piatak M, Lifson JD, Pope M, Cunningham AL. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 2004;103:2170-2179.
98. Lekkerkerker AN, van Kooyk Y, Geijtenbeek TB. Viral piracy: HIV-1 targets dendritic cells for transmission. Curr HIV Res 2006;4:169-176.
99. Sol-Foulon N, Moris A, Nobile C, Boccaccio C, Engering A, Abastado JP, Heard JM, van Kooyk Y, Schwartz O. HIV-1 Nef-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity 2002;16:145-155.
100. Satomi M, Shimizu M, Shinya E, Watari E, Owaki A, Hidaka C, Ichikawa M, Takeshita T, Takahashi H. Transmission of macrophage-tropic HIV-1 by breast-milk macrophages via DC-SIGN. J Infect Dis 2005;191:174-181.
101. Coovadia H, Kindra G. Breastfeeding to prevent HIV transmission in infants: Balancing pros and cons. Curr Opin Infect Dis 2008;21:11-15.
102. Naarding MA, Ludwig IS, Groot F, Berkhout B, Geijtenbeek TB, Pollakis G, Paxton WA. Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+T lymphocytes. J Clin Invest 2005;115:3256-3264.
103. Naarding MA, Dirac AM, Ludwig IS, Speijer D, Lindquist S, Vestman E-L, Stax MJ, Geijtenbeek TBH, Pollakis G, Hernell O, Paxton WA. Bile salt-stimulated lipase from human milk binds DC-SIGN and inhibits human immunodeficiency virus type 1 transfer to CD4+T cells. Antimicrob Agents Chemother 2006;50:3367-3374.
104. Saeland E, de Jong MA, Nabatov AA, Kalay H, Geijtenbeek TB, van Kooyk Y. MUC1 in human milk blocks transmission of human immunodeficiency virus from dendritic cells to T cells. Mol Immunol 2009;46:2309-2316.
105. Requena M, Bouhlal H, Nasreddine N, Saidi H, Gody JC, Aubry S, Gresenguet G, Kazatchkine MD, Sekaly RP, Belec L, Hocini H. Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins. Immunology 2008;123:508-518.
106. Soilleux EJ, Barten R, Trowsdale J. DC-SIGN; a related gene, DC-SIGNR; and CD23 form a cluster on 19p13. J Immunol 2000;165:2937-2942.
107. Pohlmann S, Soilleux EJ, Baribaud F, Leslie GJ, Morris LS, Trowsdale J, Lee B, Coleman N, Doms RW. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci USA 2001;98:2670-2675.
108. Halary F, Amara A, Lortat-Jacob H, Messerle M, Delaunay T, Houles C, Fieschi F, Arenzana-Seisdedos F, Moreau JF, Dechanet-Merville J. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Immunity 2002;17:653-664.
109. Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci USA 2003;100:4498-4503.
110. Marzi A, Gramberg T, Simmons G, Moller P, Rennekamp AJ, Krumbiegel M, Geier M, Eisemann J, Turza N, Saunier B, Steinkasserer A, Becker S, Bates P, Hofmann H, Pohlmann S. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol 2004;78:12090-12095.
111. Simmons G, Reeves JD, Grogan CC, Vandenberghe LH, Baribaud F, Whitbeck JC, Burke E, Buchmeier MJ, Soilleux EJ, Riley JL, Doms RW, Bates P, Pohlmann S. DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 2003;305:115-123.
112. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, Delgado R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 2002;76:6841-6844.
113. Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, Virelizier JL, Arenzana-Seisdedos F, Despres P. Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 2003;4:723-728.
114. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, Eller MA, Pattanapanyasat K, Sarasombath S, Birx DL, Steinman RM, Schlesinger S, Marovich MA. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 2003;197:823-829.
115. Jain P, Manuel SL, Khan ZK, Ahuja J, Quann K, Wigdahl B. DC-SIGN mediates cell-free infection and transmission of human T-cell lymphotropic virus type 1 by dendritic cells. J Virol 2009;83:10908-10921.
116. Valladeau J, Duvert-Frances V, Pin JJ, Dezutter-Dambuyant C, Vincent C, Massacrier C, Vincent J, Yoneda K, Banchereau J, Caux C, Davoust J, Saeland S. The monoclonal antibody DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and is rapidly internalized from the cell surface. Eur J Immunol 1999;29:2695-2704.
117. Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y, Duvert-Frances V, Vincent C, Schmitt D, Davoust J, Caux C, Lebecque S, Saeland S. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000;12:71-81.
118. Stambach NS, Taylor ME. Characterization of carbohydrate recognition by langerin, a C-type lectin of Langerhans cells. Glycobiology 2003;13:401-410.
119. Chatwell L, Holla A, Kaufer BB, Skerra A. The carbohydrate recognition domain of Langerin reveals high structural similarity with the one of DC-SIGN but an additional, calcium-independent sugar-binding site. Mol Immunol 2008;45:1981-1994.
120. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, Orenstein JM, Zimmerman PA, Blauvelt A. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci USA 2003;100:8401-8406.
121. de Witte L, Nabatov A, Pion M, Fluitsma D, de Jong MA, de Gruijl T, Piguet V, van Kooyk Y, Geijtenbeek TB. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med 2007;13:367-371.
122. Fahrbach KM, Barry SM, Ayehunie S, Lamore S, Klausner M, Hope TJ. Activated CD34-derived Langerhans cells mediate transinfection with human immunodeficiency virus. J Virol 2007;81:6858-6868.
123. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003;1:25-34.
124. Maher D, Wu X, Schacker T, Horbul J, Southern P. HIV binding, penetration, and primary infection in human cervicovaginal tissue. Proc Natl Acad Sci USA 2005;102:11504-11509.
125. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000;74:5577-5586.
126. Apostolopoulos V, McKenzie IF. Role of the mannose receptor in the immune response. Curr Mol Med 2001;1:469-474.
127. Taylor ME, Conary JT, Lennartz MR, Stahl PD, Drickamer K. Primary structure of the mannose receptor contains multiple motifs resembling carbohydrate-recognition domains. J Biol Chem 1990;265:12156-12162.
128. Stahl PD, Ezekowitz RAB. The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol 1998;10:50-55.
129. Nguyen DG, Hildreth JE. Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur J Immunol 2003;33:483-493.
130. Lai J, Bernhard OK, Turville SG, Harman AN, Wilkinson J, Cunningham AL. Oligomerization of the Macrophage Mannose Receptor Enhances gp120-mediated Binding of HIV-1. J Biol Chem 2009;284:11027-11038.
131. Trujillo JR, Rogers R, Molina RM, Dangond F, McLane MF, Essex M, Brain JD. Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Proc Natl Acad Sci USA 2007;104:5097-5102.
132. Fraser IP, Koziel H, Ezekowitz RA. The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol 1998;10:363-372.
133. Jack DL, Klein NJ, Turner MW. Mannose-binding lectin: Targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 2001;180:86-99.
134. Weis WI, Drickamer K. Structural basis of lectin-carbohydrate recognition. Annu Rev Biochem 1996;65:441-473.
135. Mitchell DA, Fadden AJ, Drickamer K. A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem 2001;276:28939-28945.
136. Geijtenbeek TBH, van Vliet SJ, Engering A, 't Hart BA, van Kooyk Y. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 2004;22:33-54.
137. Ezekowitz RAB, Kuhlman M, Groopman JE, Byrn RA. A human-serum mannose-binding protein inhibits invitro infection by the human immunodeficiency virus. J Exp Med 1989;169:185-196.
138. Saifuddin M, Hart ML, Gewurz H, Zhang Y, Spear GT. Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. J Gen Virol 2000;81:949-955.
139. Ying HY, Ji X, Hart ML, Gupta K, Saifuddin M, Zariffard MR, Spear GT. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retroviruses 2004;20:327-335.
140. Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS 1993;7:1307-1313.
141. Madsen J, Kliem A, Tornoe I, Skjodt K, Koch C, Holmskov U. Localization of lung surfactant protein D on mucosal surfaces in human tissues. J Immunol 2000;164:5866-5870.
142. Husby S, Herskind AM, Jensenius JC, Holmskov U. Heritability estimates for the constitutional levels of the collectins mannan-binding lectin and lung surfactant protein D. A study of unselected like-sexed mono- and dizygotic twins at the age of 6-9 years. Immunology 2002;106:389-394.
143. Meschi J, Crouch EC, Skolnik P, Yahya K, Holmskov U, Leth-Larsen R, Tornoe I, Tecle T, White MR, Hartshorn KL. Surfactant protein D binds to human immunodeficiency virus (HIV) envelope protein gp120 and inhibits HIV replication. J Gen Virol 2005;86:3097-3107.
144. Gaiha GD, Dong T, Palaniyar N, Mitchell DA, Reid KB, Clark HW. Surfactant protein A binds to HIV and inhibits direct infection of CD4+cells, but enhances dendritic cell-mediated viral transfer. J Immunol 2008;181:601-609.
145. Lambert AA, Gilbert C, Richard M, Beaulieu AD, Tremblay MJ. The C-type lectin surface receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells and contributes to trans- and cis-infection pathways. Blood 2008;112:1299-1307.
146. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002;76:7293-7305.
147. Scanlan CN, Pantophlet R, Wormald MR, Saphire EO, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha 1 ->2 mannose residues on the outer face of gp120. J Virol 2002;76:7306-7321.
148. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003;300:2065-2071.
149. Astronomo RD, Lee HK, Scanlan CN, Pantophlet R, Huang CY, Wilson IA, Blixt O, Dwek RA, Wong CH, Burton DR. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J Virol 2008;82:6359-6368.
150. Joyce JG, Krauss IJ, Song HC, Opalka DW, Grimm KM, Nahas DD, Esser MT, Hrin R, Feng M, Dudkin VY, Chastain M, Shiver JW, Danishefsky SJ. An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions. Proc Natl Acad Sci USA 2008;105:15684-15689.
151. Krauss IJ, Joyce JG, Finnefrock AC, Song HC, Dudkin VY, Geng X, Warren JD, Chastain M, Shiver JW, Danishefsky SJ. Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody. J Am Chem Soc 2007;129:11042-11044.
152. Luallen RJ, Fu H, Agrawal-Gamse C, Mboudjeka I, Huang W, Lee FH, Wang LX, Doms RW, Geng Y. A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN. J Virol 2009;83:4861-4870.
153. Luallen RJ, Lin JQ, Fu H, Cai KK, Agrawal C, Mboudjeka I, Lee FH, Montefiori D, Smith DF, Doms RW, Geng Y. An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. J Virol 2008;82:6447-6457.
154. Wang J, Li H, Zou G, Wang LX. Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study. Org Biomol Chem 2007;5:1529-1540.
155. Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, Wong CH. Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci USA 2008;105:3690-3695.
156. Lehrer RI, Lichtenstein AK, Ganz T. Defensins: Antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol 1993;11:105-128.
157. Zhao C, Nguyen T, Liu L, Sacco RE, Brogden KA, Lehrer RI. Gallinacin-3, an inducible epithelial beta-defensin in the chicken. Infect Immun 2001;69:2684-2691.
158. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol 2002;14:96-102.
159. Cole AM, Hong T, Boo LM, Nguyen T, Zhao C, Bristol G, Zack JA, Waring AJ, Yang OO, Lehrer RI. Retrocyclin: A primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci USA 2002;99:1813-1818.
160. Munk C, Wei G, Yang OO, Waring AJ, Wang W, Hong T, Lehrer RI, Landau NR, Cole AM. The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res Hum Retroviruses 2003;19:875-881.
161. Wang W, Cole AM, Hong T, Waring AJ, Lehrer RI. Retrocyclin, an antiretroviral theta-defensin, is a lectin. J Immunol 2003;170:4708-4716.
162. Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI. Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 2004;173:515-520.
163. Gallo SA, Wang W, Rawat SS, Jung G, Waring AJ, Cole AM, Lu H, Yan X, Daly NL, Craik DJ, Jiang S, Lehrer RI, Blumenthal R. Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 2006;281:18787-18792.
164. Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P. alpha-defensins block the early steps of HIV-1 infection: Interference with the binding of gp120 to CD4. Blood 2007;109:2928-2935.
165. Feng Z, Dubyak GR, Lederman MM, Weinberg A. Cutting Edge: Human beta Defensin 3-A Novel Antagonist of the HIV-1 Coreceptor CXCR4. J Immunol 2006;177:782-786.
166. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993;6:1-21.
167. Ueki T, Oka M, Fukagawa Y, Oki T. Studies on the mode of antifungal action of pradimicin antibiotics. III. Spectrophotometric sequence analysis of the ternary complex formation of BMY-28864 with D-mannopyranoside and calcium. J Antibiot (Tokyo) 1993;46:465-477.
168. Hoshino H, Seki J, Takeuchi T. New antifungal antibiotics, benanomicins A and B inhibit infection of T-cell with human immunodeficiency virus (HIV) and syncytium formation by HIV. J Antibiot (Tokyo) 1989;42:344-346.
169. Tanabe A, Nakashima H, Yoshida O, Yamamoto N, Tenmyo O, Oki T. Inhibitory Effect of New Antibiotic, Pradimicin-a on Infectivity, Cytopathic Effect and Replication of Human Immunodeficiency Virus Invitro. J Antibiot (Tokyo) 1988;41:1708-1710.
170. Balzarini J, Van Laethem K, Daelemans D, Hatse S, Bugatti A, Rusnati M, Igarashi Y, Oki T, Schols D. Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus. J Virol 2007;81:362-373.
171. Balzarini J, François KO, Van Laethem K, Hoorelbeke B, Renders M, Auwerx J, Liekens S, Oki T, Igarashi Y, Schols D. Pradimicin S, a highly-soluble non-peptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use. Antimicrob Agents Chemother 2010;54:1425-1435.
172. François KO, Pannecouque C, Auwerx J, Lozano V, Perez-Perez MJ, Schols D, Balzarini J. The phtalocyanine prototype derivative Alcian Blue: The first synthetic agent with selective anti-human immunodeficiency virus activity due to its gp120 glycan-binding potential. Antimicrob Agents Chemother 2009;53:4852-4859.
173. Dwek RA, Butters TD, Platt FM, Zitzmann N. Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov 2002;1:65-75.
174. Fischer PB, Collin M, Karlsson GB, James W, Butters TD, Davis SJ, Gordon S, Dwek RA, Platt FM. The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J Virol 1995;69:5791-5797.
175. Pollock S, Dwek RA, Burton DR, Zitzmann N. N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. AIDS 2008;22:1961-1969.
176. Balzarini J. The alpha(1, 2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120. FEBS Lett 2007;581:2060-2064.
177. Kajimoto T, Node M. Inhibitors Against Glycosidases as Medicines. Curr Top Med Chem 2009;9:13-33.
178. Wrodnigg TM, Steiner AJ, Ueberbacher BJ. Natural and synthetic iminosugars as carbohydrate processing enzyme inhibitors for cancer therapy. Anticancer Agents Med Chem 2008;8:77-85.
179. Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebicek M, Platt FM, Butters TD, Dwek RA, Zimran A. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004;27:757-766.
180. Calfee DP, Hayden FG. New approaches to influenza chemotherapy-Neuraminidase inhibitors. Drugs 1998;56:537-553.
181. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: Systematic review and meta-analysis. Br Med J 2009;339:b5106.
182. Martinez-Avila O, Bedoya LM, Marradi M, Clavel C, Alcami J, Penades S. Multivalent manno-glyconanoparticles inhibit DC-SIGN-mediated HIV-1 trans-infection of human T cells. Chembiochem 2009;10:1806-1809.
183. Martinez-Avila O, Hijazi K, Marradi M, Clavel C, Campion C, Kelly C, Penades S. Gold manno-glyconanoparticies: Multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN. Chem Eur J 2009;15:9874-9888.
184. Rojo J, Delgado R. Glycodendritic structures: Promising new antiviral drugs. J Antimicrob Chemother 2004;54:579-581.
185. Tabarani G, Reina JJ, Ebel C, Vives C, Lortat-Jacob H, Rojo J, Fieschi F. Mannose hyperbranched dendritic polymers interact with clustered organization of DC-SIGN and inhibit gp120 binding. FEBS Lett 2006;580:2402-2408.
186. Balzarini J. Targeting the glycans of gp120: A novel approach aimed at the Achilles heel of HIV. Lancet Infect Dis 2005;5:726-731.
187. Balzarini J, Van Laethem K, Hatse S, Vermeire K, De Clercq E, Peumans W, Van Damme E, Vandamme AM, Bolmstedt A, Schols D. Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J Virol 2004;78:10617-10627.
188. Balzarini J, Van Herrewege Y, Vermeire K, Vanham G, Schols D. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol 2007;71:3-11.
189. Turville SG, Vermeire K, Balzarini J, Schols D. Sugar-binding proteins potently inhibit dendritic cell human immunodeficiency virus type 1 (HIV-1) infection and dendritic-cell-directed HIV-1 transfer. J Virol 2005;79:13519-13527.
190. Auwerx J, Francois KO, Vanstreels E, Van Laethem K, Daelemans D, Schols D, Balzarini J. Capture and transmission of HIV-1 by the C-type lectin L-SIGN (DC-SIGNR) is inhibited by carbohydrate-binding agents and polyanions. Antiviral Res 2009;83:61-70.
191. Leikina E, Delanoe-Ayari H, Melikov K, Cho MS, Chen A, Waring AJ, Wang W, Xie Y, Loo JA, Lehrer RI, Chernomordik LV. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol 2005;6:995-1001.
192. Balzarini J, Van Laethem K, Hatse S, Froeyen M, Van Damme E, Bolmstedt A, Peumans W, De Clercq E, Schols D. Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis. Mol Pharmacol 2005;67:1556-1565.
193. Balzarini J, Van Laethem K, Peumans WJ, Van Damme EJ, Bolmstedt A, Gago F, Schols D. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 2006;80:8411-8421.
194. Witvrouw M, Fikkert V, Hantson A, Pannecouque C, O'Keefe B R, McMahon J, Stamatatos L, de Clercq E, Bolmstedt A. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J Virol 2005;79:7777-7784.
195. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998;4:679-684.
196. Hu Q, Mahmood N, Shattock RJ. High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 2007;368:145-154.
197. Helenius A, Aebi M. Intracellular functions of N-linked glycans. Science 2001;291:2364-2369.
198. Auwerx J, Francois KO, Covens K, Van Laethem K, Balzarini J. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. Virology 2008;382:10-19.
199. Wolk T, Schreiber M. N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med Microbiol Immunol (Berl) 2006;195:165-172. Epub 2006 Mar 2018.
200. Willey RL, Smith DH, Lasky LA, Theodore TS, Earl PL, Moss B, Capon DJ, Martin MA. Invitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 1988;62:139-147.
201. Luallen RJ, Agrawal-Gamse C, Fu H, Smith DF, Doms RW, Geng Y. Antibodies against Man alpha 1, 2-Man alpha 1, 2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains. Glycobiology 2010;20:280-286.
202. van der Meer FJ, de Haan CA, Schuurman NM, Haijema BJ, Verheije MH, Bosch BJ, Balzarini J, Egberink HF. The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins. J Antimicrob Chemother 2007;60:741-749.
203. van der Meer FJ, Schuurman NM, Balzarini J, Egberink HF. Comparative evaluation of the activity of antivirals towards feline immunodeficiency virus in different cell culture systems. Antiviral Res 2007;76:198-201.
204. Balestrieri E, Ascolani A, Igarashi Y, Oki T, Mastino A, Balzarini J, Macchi B. Inhibition of cell-to-cell transmission of human T-cell lymphotropic virus type 1 in vitro by carbohydrate-binding agents. Antimicrob Agents Chemother 2008;52:2771-2779.
205. O'Keefe BR, Smee DF, Turpin JA, Saucedo CJ, Gustafson KR, Mori T, Blakeslee D, Buckheit R, Boyd MR. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother 2003;47:2518-2525.
206. Butters TD, Yudkin B, Jacob GS, Jones IM. Structural characterization of the N-linked oligosaccharides derived from HIVgp120 expressed in lepidopteran cells. Glycoconj J 1998;15:83-88.
207. Tailleux L, Schwartz O, Herrmann JL, Pivert E, Jackson M, Amara A, Legres L, Dreher D, Nicod LP, Gluckman JC, Lagrange PH, Gicquel B, Neyrolles O. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J Exp Med 2003;197:121-127.
208. Koppel EA, Saeland E, de Cooker DJM, van Kooyk Y, Geijtenbeek TBH. DC-SIGN specifically recognizes Streptococcus pneumoniae serotypes 3 and 14. Immunobiology 2005;210:203-210.
209. van Die I, van Vliet SJ, Nyame AK, Cummings RD, Bank CMC, Appelmelk B, Geijtenbeek TBH, van Kooyk Y. The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis x. Glycobiology 2003;13:471-478.
210. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiegne-Traore V, Uaheowitchai C, Karim SS, Masse B, Perriens J, Laga M. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 2002;360:971-977.
211. Balzarini J, Hatse S, Vermeire K, Princen K, Aquaro S, Perno CF, De Clercq E, Egberink H, Vanden Mooter G, Peumans W, Van Damme E, Schols D. Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother 2004;48:3858-3870.
212. Hillier SL. The vaginal microbial ecosystem and resistance to HIV. AIDS Res Hum Retroviruses 1998;14:S17-S21.
213. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F. In vitro and in vivo-The story of Nonoxynol 9. J Acquir Immune Defic Syndr 2005;39:1-8.
214. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463-472.
215. Mesquita PMM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioglu E, Keller MJ, Herold BC. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: Model of microbicide safety. J Infect Dis 2009;200:599-608.
216. Roehr B. Microbicide offers no protection against HIV infection. Br Med J 2009;339:b5538.
217. Jenabian MA, Saidi H, Charpentier C, Van Herrewege Y, Son JC, Schols D, Balzarini J, Vanham G, Belec L. In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). J Antimicrob Chemother 2009;64:1192-1195.
218. De Keersmaecker SC, Verhoeven TL, Desair J, Marchal K, Vanderleyden J, Nagy I. Strong antimicrobial activity of Lactobacillus rhamnosus GG against Salmonella typhimurium is due to accumulation of lactic acid. FEMS Microbiol Lett 2006;259:89-96.
219. Lebeer S, Vanderleyden J, De Keersmaecker SCJ. Host interactions of probiotic bacterial surface molecules: Comparison with commensals and pathogens. Nat Rev Microbiol 2010;8:171-184.
220. Giomarelli B, Provvedi R, Meacci F, Maggi T, Medaglini D, Pozzi G, Mori T, McMahon JB, Gardella R, Boyd MR. The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. Aids 2002;16:1351-1356.
221. Liu X, Lagenaur LA, Simpson DA, Essenmacher KP, Frazier-Parker CL, Liu Y, Tsai D, Rao SS, Hamer DH, Parks TP, Lee PP, Xu Q. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother 2006;50:3250-3259.
222. Stoiber H, Kacani L, Speth C, Wurzner R, Dierich MP. The supportive role of complement in HIV pathogenesis. Immunol Rev 2001;180:168-176.
223. Banki Z, Stoiber H, Dierich MP. HIV and human complement: Inefficient virolysis and effective adherence. Immunol Lett 2005;97:209-214.
224. Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME. Essentials of glycobiology. New York: Cold Spring Harbor Laboratory Press, Cold Spring Harbor; 2009.
225. Fouquaert E, Smith DF, Peumans WJ, Proost P, Balzarini J, Savvides SN, Damme EJ. Related lectins from snowdrop and maize differ in their carbohydrate-binding specificity. Biochem Biophys Res Commun 2009;380:260-265.
226. Stillmark H. Über Ricin ein giftiges Ferment aus den Samen von Ricinus communis L. und einige anderen Euphorblaceen. Inaugural Dissertation Dorpat, Tartu 1888.
227. Cooper HL, Rubin AD. Synthesis of nonribosomal RNA by lymphocytes: A response to phytohemagglutinin treatment. Science 1966;152:516-518.
228. Koshte VL, Aalbers M, Calkhoven PG, Aalberse RC. The potent Igg4-inducing antigen in banana is a mannose-binding lectin, banlec-I. Int Arch Allergy Imm 1992;97:17-24.
229. Tchernychev B, Rabinkov A, Mirelman D, Wilchek M. Natural antibodies to dietary proteins-the existence of natural antibodies to alliinase (alliin lyase) and mannose-specific lectin from garlic (allium-sativum) in human serum. Immunol Lett 1995;47:53-57.
230. Tchernychev B, Wilchek M. Natural human antibodies to dietary lectins. FEBS Lett 1996;397:139-142.
231. Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat Rev Immunol 2008;8:874-887.
232. Favero J, Corbeau P, Nicolas M, Benkirane M, Travé G, Dixon JFP, Aucouturier P, Rasheed S, Parker JW, Liautard JP, Devaux C, Dornand J. Inhibition of human immunodeficiency virus infection by the lectin jacalin and by a derived peptide showing a sequence similarity with gp120. Eur J Immunol 1993;23:179-185.
233. Reyes-Lopez CA, Hernandez-Santoyo A, Pedraza-Escalona M, Mendoza G, Hernandez-Arana A, Rodriguez-Romero A. Insights into a conformational epitope of Hev b 6.02 (hevein). Biochem Biophys Res Commun 2004;314:123-130.
234. Harata K, Muraki M. Crystal structures of urtica dioica agglutinin and its complex with tri-N-acetylchitotriose. J Mol Biol 2000;297:673-681.
235. Hester G, Kaku H, Goldstein IJ, Wright CS. Structure of mannose-specific snowdrop (galanthus nivalis) lectin is representative of a new plant lectin family (Vol 2, Pg 472, 1995). Nat Struct Biol 1995;2:704-704.
236. Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, Doms RW, Moore JP. N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology 2008;372:187-200.